Goldenwell Biotech, Inc.
Other OTCTotal Valuation
Goldenwell Biotech, Inc. carries a market capitalization of 89.10M, placing it among publicly traded companies globally. Its enterprise value stands at 97.80M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 89.10M |
| Enterprise Value | 97.80M |
Share Statistics
Goldenwell Biotech, Inc. currently has 99.00M shares outstanding.
| Shares Outstanding | 99.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.78M, and the price-to-book ratio stands at -58.73.
| PE Ratio | N/A |
| PS Ratio | 1.78M |
| PB Ratio | -58.73 |
| P/TBV Ratio | -270.45 |
| P/FCF Ratio | -26,310.36 |
| P/OCF Ratio | -26,310.36 |
Enterprise Valuation
| EV / Sales | 1.78M |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 20,870.43 |
Financial Position
Goldenwell Biotech, Inc. maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -26.46, indicating conservative leverage, while an interest coverage ratio of -12.88 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.19 |
| Quick Ratio | 0.13 |
| Debt / Equity | -26.46 |
| Debt / EBITDA | -0.88 |
| Interest Coverage | -12.88 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -261.59 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.00 |
Stock Price Statistics
Goldenwell Biotech, Inc.'s stock has gained approximately 350% over the past 52 weeks. The 50-day moving average sits at 0.67, while the 200-day moving average is 1.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | 350% |
| 50-Day Moving Average | 0.67 |
| 200-Day Moving Average | 1.55 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Goldenwell Biotech, Inc. generated 55.00 in revenue and converted that into -275,541.00 in net income, yielding earnings per share of 0.00. EBITDA reached -108,225.00, while operating income came in at -108,225.00.
| Revenue | 55.00 |
| Gross Profit | 12.00 |
| Operating Income | -108,225.00 |
| Pretax Income | -275,541.00 |
| Net Income | -275,541.00 |
| EBITDA | -108,225.00 |
| EBIT | -108,225.00 |
| Earnings Per Share (EPS) | 0.00 |
Balance Sheet
Goldenwell Biotech, Inc. holds 13,414.00 in cash and equivalents against 95,588.00 in total debt, resulting in a net debt position of 82,174.00. Total book value stands at -1.66M, with working capital of -81,246.00 providing operational flexibility.
| Cash & Cash Equivalents | 13,414.00 |
| Total Debt | 95,588.00 |
| Net Debt | 82,174.00 |
| Equity (Book Value) | -1.66M |
| Book Value Per Share | -0.02 |
| Working Capital | -81,246.00 |
Cash Flow
Goldenwell Biotech, Inc. produced -3,714.00 in operating cash flow over the past twelve months.
| Operating Cash Flow | -3,714.00 |
| Capital Expenditures | N/A |
| Free Cash Flow | -3,714.00 |
| FCF Per Share | 0.00 |
Margins
Goldenwell Biotech, Inc. operates with a gross margin of 21.82, reflecting its pricing power and cost economics. The operating margin of -196,772.73 and net profit margin of -500,983.64 provide insight into operational efficiency.
| Gross Margin | 21.82 |
| Operating Margin | -196,772.73 |
| Pretax Margin | -500,983.64 |
| Profit Margin | -500,983.64 |
| EBITDA Margin | -196,772.73 |
Scores
Goldenwell Biotech, Inc. posts an Altman Z-Score of 5.08, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 5.08 |